Tunneling nanotubes: A versatile target for cancer therapy.

Tunneling nanotubes: A versatile target for cancer therapy.

Curr Cancer Drug Targets. 2017 Nov 29;:

Authors: Sahoo P, Jena SR, Samanta L

Abstract
Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) are common acute leukemia in adults and children respectively. In therapy process of these malignancies, chemotherapy is the main strategy that fails in many of cases. Moreover, chemotherapy is usually associated with adverse effects it also damages the healthy cells. In this regard, development of new therapies is essential. Monoclonal antibodies directed to the cell surface markers of leukemic blasts may have promising consequences. These tools can provide a specific cell targeting with minimal toxic effects on other normal cells. In this project, CD45Ra+ cells and CD123+ cells, two considered surface marker of leukemic blasts in AML and ALL respectively, were targeted by specific monoclonal antibodies. Cytotoxicity effect and cell death induction were determined by MTT assay and flow cytometry. Changes in expression profile of MCL1, cMyc, Survivin, Id1 and PIM1 genes were assessed by real time PCR after cell treatment with anti-CD45Ra and/or anti-CD123 monoclonal antibodies. Statistical analysis of results showed an effective antibody-mediated cytotoxicity and induction of apoptosis in KG1α (CD45Ra+) and Nalm6 (CD123+) cell lines. Also, a significant change in expression level of some of the apoptosis-related genes were observed. According to the results of this study, it can be concluded that an effective targeting of AML and ALL cells can be performed by anti-CD45Ra and anti-CD123 monoclonal antibodies through their effector functions and apoptosis induction.

PMID: 29189162 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/2zUfDnx
via IFTTT